

[0119] 33. Motoyama, K., Inoue, H., Takatsuno, Y., Tanaka, F., Mimori, K., Uetake, H., Sugihara, K. and Mori, M. (2009) Over- and under-expressed microRNAs in human colorectal cancer. *Int J Oncol*, 34, 1069-75.

[0120] 34. Earle, J. S., Luthra, R., Romans, A., Abraham, R., Ensor, J., Yao, H. and Hamilton, S. R. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. *J Mol Diagn*, 12, 433-40.

What is claimed is:

1. A method for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of:

obtaining one or more biological samples from the subject suspected of suffering from colorectal neoplasia;

measuring an overall expression pattern or level of one or more microRNAs obtained from the one or more biological samples of the subject; and

comparing the overall expression pattern of the one or more microRNAs from the biological sample of the subject suspected of suffering from colorectal neoplasia with the overall expression pattern of the one or more microRNAs from a biological sample of a normal subject, wherein the normal subject is a healthy subject not suffering from colorectal neoplasia, wherein overexpression of a combination of miR19a and miR19b, or miR19a and miR19b and miR15b is indicative of colorectal cancer.

2. The method of claim 1, further comprising the analysis of at least one of miR18a, miR29a, or miR335 as compared to expression from the normal subject, wherein overexpression of miR18a, miR29a, or miR335 is indicative of colorectal neoplasia.

3. The method of claim 1, further comprising the analysis of at least one of miR29a, miR92a, or miR141.

4. The method of claim 1, wherein the one or more biological samples are selected from the group consisting of one or more biological fluids, a plasma sample, a serum sample, a blood sample, a tissue sample, or a fecal sample.

5. The method of claim 1, wherein the method is capable of detecting early CRC (I-II) as accurately as advanced CRC (stage II-III), right-sided tumors and left-sided lesions.

6. The method of claim 1, wherein the method comprises confidence interval that is 90, 91, 92, 93, 94, or 95% of greater.

7. The method of claim 1, wherein the method further comprises determining of the level of expression of microRNAs that are underexpressed in colorectal neoplasia are selected from:

---

hsa-miR-636;  
 hsa-miR-876-3p;  
 hsa-miR-1537;  
 hsa-miR-630;  
 hsa-miR-380\*;  
 hsa-miR-338-5p;  
 hsa-miR-573;  
 hsa-miR-182\*;  
 hsa-miR-518c\*;  
 hsa-miR-187\*;  
 hsa-miR-1233;  
 hsa-miR-449b;  
 hsa-miR-1204;  
 hsa-miR-518d-3p;  
 hsa-miR-1290;  
 hsa-miR-1449.1;  
 hsa-miR-105;

-continued

---

hsa-miR-298;  
 hsa-miR-491-5p;  
 hsa-miR-576-3p;  
 hsa-miR-590-3p;  
 hsa-miR-1257;  
 hsa-miR-1225-3p;  
 hsa-miR-127-3p;  
 hsa-miR-936;  
 hsa-miR-379;  
 hsa-miR-664\*;  
 hsa-miR-548j;  
 hsa-miR-130b\*;  
 and  
 hsa-miR-515-3p.

---

8. The method of claim 1, wherein the method further comprises determining of the level of expression of microRNAs that are overexpressed in colorectal neoplasia are selected from:

---

hsa-miR-302b;  
 hsa-miR-125a-5p;  
 hsa-miR-424;  
 hsa-miR-125b;  
 hsa-miR-100;  
 hsa-miR-768-3p:11.0;  
 hsa-miR-24;  
 hsa-miR-23a;  
 hsa-miR-1274b;  
 hsa-miR-27a;  
 hsa-miR-26b;  
 hsa-miR-30d;  
 hsa-miR-520h;  
 hsa-miR-520g;  
 hsa-miR-302\*;  
 hsa-miR-518c;  
 hsa-miR-335;  
 hsa-miR-29a;  
 hsa-miR-152;  
 hsa-miR-191;  
 hsa-miR-17;  
 hsa-miR-19b;  
 hsa-miR-30a;  
 hsa-miR-151-5p;  
 hsa-miR-92a;  
 hsa-miR-25;  
 hsa-miR-15b;  
 hsa-miR-15a;  
 hsa-miR-30e\*;  
 hsa-miR-132\*;  
 and  
 hsa-miR-921.

---

9. The method of claim 1, wherein the expression level of the one or more microRNAs is measured by microarray expression profiling, PCR, reverse transcriptase PCR, reverse transcriptase real-time PCR, quantitative real-time PCR, end-point PCR, multiplex end-point PCR, cold PCR, ice-cold PCR, mass spectrometry, in situ hybridization (ISH), multiplex in situ hybridization, or nucleic acid sequencing.

10. The method of claim 1, wherein the method is used for treating a patient at risk or suffering from colorectal neoplasia, selecting an anti-neoplastic agent therapy for a patient at risk or suffering from colorectal neoplasia, stratifying a patient to a subgroup of colorectal neoplasia or for a colorectal neoplasia therapy clinical trial, determining resistance or responsiveness to a colorectal neoplasia therapeutic regimen, developing a kit for diagnosis of colorectal neoplasia or any combinations thereof.